文献速递冠心病外科

全静脉桥与冠状动脉旁路移植术后极长期生存

All-Venous Grafting and Very Long-Term Survival After Coronary Artery Bypass Grafting.
PubMed 文献 · Ann Thorac Surg · 2025-10-22

该回顾性研究分析1999至2004年接受CABG的640116例Medicare受益人,比较全静脉桥与单动脉桥的生存差异。经重叠倾向评分加权调整后,全静脉桥的30天、1年及20年限制性平均生存时间均显著劣于单动脉桥。结论支持现行指南将至少1根动脉桥列为I类推荐。

要点

  • 全静脉桥较单动脉桥风险调整后30天、1年及20年生存均更差。
  • 20年RMST差异为1.21年,支持至少使用1根动脉桥。
  • 研究为观察性设计,需RCT进一步验证。

核心结论

  • 全静脉桥CABG患者的风险调整后生存劣于单动脉桥患者。
  • 结果支持现行多学科指南将至少1根动脉桥列为I类推荐。

研究设计与样本

  • 回顾性分析1999至2004年接受CABG的640116例Medicare受益人。
  • 比较全静脉桥与单动脉桥的生存,采用限制性平均生存时间(RMST)。
  • 使用重叠倾向评分加权对所有可用协变量进行风险调整。

主要发现

  • 全静脉桥101120例(15.8%),单动脉桥538996例(84.2%)。

临床怎么用

  • 在CABG中应至少使用1根动脉桥以改善极长期生存。
  • 全静脉桥策略仅适用于无法获取动脉桥的特殊情况。

局限性

  • 研究为观察性回顾性分析,非随机对照试验。
  • 数据来源为Medicare受益人,结论外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Observational studies of coronary artery bypass grafting (CABG) have associated single-arterial grafting with superior outcomes compared with all-venous grafting. Current guidelines assign single-arterial grafting a class I recommendation. However, no adequately powered randomized controlled trials were undertaken to confirm this benefit, and very long-term data on outcomes of various conduit strategies from more contemporary eras remain lacking. METHODS: This study retrospectively analyzed Medicare beneficiaries who underwent CABG from 1999 to 2004, the period immediately preceding the first publication of guidelines affording single-arterial grafting a class I indication. The study compared survival between beneficiaries undergoing all-venous grafting and those undergoing single-arterial grafting by using restricted mean survival times (RMSTs). Risk adjustment was performed for all available covariates by using overlap propensity score weighting. RESULTS: Among 640,116 Medicare beneficiaries, 101,120 (15.8%) underwent all-venous grafting and 538,996 (84.2%) underwent single-arterial grafting. Beneficiaries undergoing all-venous grafting, vs single-arterial grafting, were noted to have worse risk-adjusted operative survival (30-day RMST, 28.6 [95% CI: 28.6-28.7] days vs 29.3 [95% CI: 29.2-29.3] days; difference, 0.73 [95% CI: 0.73-0.73] days; P < .001), short-term survival (1-year RMST, 324 [95% CI: 324-325] days vs 339 [95% CI: 338-339] days; difference, 14 [95% CI: 13-15] days; P < .001), and very long-term survival (20-year RMST, 8.34 [95% CI: 8.30-8.38] vs 9.55 [95% CI: 9.51-9.59] years; difference, 1.21 years; P < .001). CONCLUSIONS: Medicare beneficiaries undergoing CABG with all-venous grafting had inferior risk-adjusted survival compared with patients receiving single-arterial grafting. These findings support current multidisciplinary guideline recommendations offering a class I indication for use of at least 1 arterial graft during CABG.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Squiers JJ, Shih E, DiMaio JM, et al. All-Venous Grafting and Very Long-Term Survival After Coronary Artery Bypass Grafting. Ann Thorac Surg. 2025. PMID: 41135855. doi:10.1016/j.athoracsur.2025.09.037

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。